Significant progress in preclinical pipeline targeting KRAS-driven solid tumor cancers with systemic administration ...

Grand Cayman, Cayman Islands, March 18, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA ...

This article was originally published on Quiver News, read the full story. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of ...

Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference ...

Convertible Series A Preferred Shares (NIS 0.09 par value, 0 and 56,667 shares authorized as of December 31, 2024 and 2023, 0 and 43,121 shares issued and outstanding as of December 31, 2024 and ...

Maxim lowered the firm’s price target on Silexion Therapeutics (SLXN) to $5 from $9 and keeps a Buy rating on the shares after its Q4 results. The ...

Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today reported ...

Silexion Therapeutics' Latest Data Demonstrates that Subcutaneously Administered SIL204 Reduces Both Primary Tumors and Metastases in Clinically Relevant Orthotopic Models Where Human Pancreatic ...

Silexion Therapeutics Corp (NASDAQ:SLXN), a biopharmaceutical company with a market capitalization of $10.77 million, announced on Monday that it has entered into an agreement to retire a ...

Silexion Therapeutics Corp (NASDAQ:SLXN), a biopharmaceutical company with a market capitalization of $10.77 million, announced on Monday that it has entered into an agreement to retire a convertible ...